AK105 Injection

· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AK105 Injection, covering 2020-06-17 to 2020-06-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors [Phase 2]

See pricing